In early October, the Japanese Heart Failure Society (JHFS) held its first annual scientific meeting since it published a focused update of the heart failure treatment guidelines in March jointly with the Japanese Circulation Society. The confab featured a series…
ORGANIZATION
5% Discrepancy Line a Bad Surprise, FPMAJ Exec Says Drug Prices Will Now Go Down at Double Speed with Annual Re-Pricing
The pharma industry was “stunned” by the unexpectedly broad product coverage agreed upon for Japan’s first “off-year” re-pricing in April 2021, Toshihiko Miyajima, director general of the Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ), tells Jiho. Drug prices will…
To read the full story
Related Article
- Japan Govt Should Change Course on Consistent Price Cuts for On-Patent Drugs: FPMAJ Exec
March 22, 2021
- MHLW Announces New Drug Prices for 1st Off-Year Revision in April
March 5, 2021
- Special Mitigation Margin for COVID-19 Up for Debate towards FY2022 Drug Price Revision: MHLW Bureau Chief
January 15, 2021
- Chuikyo OKs Revised NHI Pricing Rules for FY2021 Drug Re-Pricing
January 14, 2021
- 3 Pharma Groups Rap Off-Year Drug Re-Pricing Plan; Generic Industry Frets Impact on Stable Supplies
December 21, 2020
- Chuikyo OKs Outline of FY2021 Off-Year Re-Pricing; Only Market Price-Linked Rules to Be Applied
December 21, 2020
- Ministers Agree on 5%-Plus Price Discrepancy Line for Off-Year Re-Pricing; 59% Coverage for Innovative Meds, 88% for LLPs, 83% for Gx
December 18, 2020
ORGANIZATION
- JGA Sets Out 5-Pronged Measures to Restore Trust in Generics
October 27, 2021
- Kenporen’s Masato Matsumoto to Take Over from Kono as Chuikyo Payer Rep
October 27, 2021
- Main Focus of INES Proposal Is Securing Resources to Reward Innovation, Not Macroeconomic Indexing
October 25, 2021
- Choseido Suspended from JGA for 5 Years after Biz Suspension Order
October 15, 2021
- EFPIA to Ponder Position on Macroeconomic Indexing with Patient Access as Top Priority, Continue Dialogue with Japan Govt
October 14, 2021
If you were able to make more money at a company you found less desirable than your current one, would it be worth it? Conversely, would you move to a better company and a better role and accept less pay?…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…